Since July 2023 only 14 serious international complaints received , being future ready for coming winter season more than 8000 batches of cough syrup tested and only 2-3 per cent failures found

 The Central Drugs Standard Control Organization (CDSCO) announced a low failure rate of just 2 per cent to 3 per cent in recent cough syrup testing of more than 8000 batches, attributing this success to effective mapping and monitoring of the supply chain.

“Importantly, these failures were not linked to Propylene glycol, a common solvent in pharmaceutical formulations. Being future ready for the coming winteds when the ghlobal cough syrup demand increases various strict steps have been taken to enhance regulatory processes, ensuring that pharmaceutical products remain safe and effective. The strategic supply chain monitoring has been crucial in maintaining high standards and minimizing failures unrelated to Propylene glycol.” Said
Dr Rajeev Singh Raghuvanshi, the Drugs Controller General of India, during the iat a session of the ongoing International Exhibition for Pharma and Healthcare ( iPHEX) 2024, a key global  event in the pharmaceutical industry being orgnaised by Phrama Export Promotion Council of India (PHARMEXCIL) along with Union Ministry of Commerce & Industry .

“Post cough syrup failure and strict measures by the Central Drugs Standard Control Organization (CDSCO) Since July 2023 only 14 international complaints have been received by the authority where remedial measures were taken and the concerned manufacturing companies and were  banned or penalized. In the last one and a half year controller has audited more than 700 manufacturing units and laboratories to improve standards “ said Dr Raghuvanshi.

“The three day pharma expo IPHEX  inaugurated by Mr Jitin Prasada, Union minister of State for Commerce & Industry  will offer the domestic industry  majors from India and all across the world a great platform to connect and do business. It will provide you with an opportunity to meet new and existing customers actively looking for new suppliers, or looking to assess the current progress of existing projects.” Said Mr Raja Bhanu  , Director General , Pharmaceutical export promotion council of India (PHARMEXCIL) speaking on the occasion.

 “The Profile of exhibits  includes Pharmaceutical Formulations, Pharmaceutical APIs, Ayush, Nutraceuticals, Health Services, Biotechnology, Biotechnology Products, R&D Services, Pharmaceutical Technologies & Consultancy, Diagnostics, Surgical Dressings, Medical Devices, Pharmaceutical Research, Clinical Trials and Custom Synthesis. More than 400 buyers from world over are participating in the International Pharma and Healthcare conglomeration. The event aims to facilitate access to quality and affordable generics on a global scale.” Said Mr Bhanu.

“IPHEX has garnered international recognition and fostered collaboration within the pharmaceutical community worldwide. India’s pharma exports during the year 2023-24 stood at USD 27.84 Billion with more than 30 percent exports to the US. About 70 % of World Health Organisation’s (WHO) vaccines under essential immunization schemes served from India. The export target for the current financial year 24-25  is US $ 31 billion ” said Mr Bhanu.